REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as the only "preferred" ...

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early ...

The investigators reported the results of a prospective, randomized, phase 3 trial studying the best individual therapy for women who have node-negative, estrogen-receptor‒positive (ER-positive) ...

Genomic Health today announced the presentation of 11 studies with the Oncotype DX breast cancer test at the 14th St. Gallen Breast Cancer Conference in Vienna, Austria. Studies presented include ...

Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database Submissions The feasibility of Oncotype DX ...

While several studies have demonstrated that the Oncotype DX Recurrence Score can help predict locoregional recurrence in patients with hormone receptor-positive breast cancer, it’s less clear whether ...

A retrospective review of the electronic medical records of 112 patients with tumors tested for the RS and the PREDICT tool was used to estimate survival benefits. The correlation between RS and ...

* Genomic Health - results from 15 Oncotype DX studies showing Oncotype Dx breast cancer test's ability to change treatment decisions in breast cancer patients Source text for Eikon: Further company ...

A gene expression test can help prevent unnecessary chemotherapy in breast cancer patients, yet its use in the Netherlands remains limited. This is shown by new research from the Netherlands ...

Dec 9 (Reuters) - Myriad Genetics Inc : * The EndoPredict test significantly outperforms the first-generation test in predicting the risk of node-negative and node-positive breast cancer recurrence ...

A team of AI and medical researchers at startup Ataraxis AI, who are also affiliated with a host of institutions across the U.S., has announced the development of an AI model that they claim is more ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American ...